Allogene Therapeutics (ALLO) Panoramica del titolo
Allogene Therapeutics, Inc. è un'azienda di immuno-oncologia in fase clinica che sviluppa e commercializza terapie con cellule T allogeniche geneticamente modificate per il trattamento del cancro e delle malattie autoimmuni. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
+ 1 più rischio
ALLO Community Fair Values
Create NarrativeSee what 27 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Allogene Therapeutics, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$2.00 |
| Massimo di 52 settimane | US$4.46 |
| Minimo di 52 settimane | US$0.98 |
| Beta | 0.46 |
| Variazione di 1 mese | -16.32% |
| Variazione a 3 mesi | -7.41% |
| Variazione di 1 anno | 83.49% |
| Variazione a 3 anni | -67.16% |
| Variazione a 5 anni | -92.06% |
| Variazione dall'IPO | -92.00% |
Notizie e aggiornamenti recenti
Recent updates
Allogene: Early ALPHA3 Data Suggests Potential Paradigm Shift For Cema-Cel In LBCL
Summary Allogene Therapeutics is positioned for a paradigm shift in CAR T therapy with cema-cel, targeting earlier, scalable intervention in high-risk LBCL. ALPHA3 interim data showed 58.3% MRD negativity for cema-cel versus 16.7% for observation, with a notably clean safety profile and outpatient feasibility. ALLO's sub-$500M enterprise value suggests the market is only partially pricing in the platform's potential, despite a sharp post-data rally. I maintain a long-term buy rating, expecting future EFS readouts to confirm Cema-Cel's best-in-class potential, though near-term volatility is likely. Read the full article on Seeking AlphaWill Allogene Therapeutics (NASDAQ:ALLO) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. By way of example, Allogene...
MRD Guided Cell Therapy And Autoimmune Focus Will Transform Long Term Opportunity
Catalysts About Allogene Therapeutics Allogene Therapeutics develops off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?
Off The Shelf CAR T Therapies Will Reshape Lymphoma And Autoimmune Treatment Trajectories
Catalysts About Allogene Therapeutics Allogene Therapeutics develops off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?
Allogeneic CAR T Expectations Will Likely Disappoint As Trial And Cash Runway Risks Mount
Catalysts About Allogene Therapeutics Allogene Therapeutics is a biotechnology company focused on developing off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?Shareholders May Find It Hard To Justify Increasing Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation For Now
Key Insights Allogene Therapeutics to hold its Annual General Meeting on 18th of June Salary of US$724.0k is part of...Here's Why We're Watching Allogene Therapeutics' (NASDAQ:ALLO) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Allogene Therapeutics: Disrupting CAR-T With A Scalable Model
Summary Allogene Therapeutics appears undervalued despite market skepticism, with a robust cash runway and potential breakthroughs in allogeneic CAR-T therapies. The company's lead asset, cema-cel, aims to shift CAR-T therapy to early intervention, potentially expanding its market and redefining treatment standards. ALLO-329 targets autoimmune diseases, positioning Allogene in a new market with significant unmet needs and less competition compared to oncology. Key risks include the efficacy and durability of allogeneic CAR-T therapies and manufacturing consistency, but early data and strategic positioning offer compelling upside potential. Read the full article on Seeking AlphaAllogene Therapeutics: Showing Promise Despite Some Shaky Safety
Summary Allogene is among the pioneers in non-self engineered cell therapy. They have demonstrated encouraging early results in lymphoma, moving aggressively into a pivotal trial in the first-line setting. Their pivotal phase 2 trial ALPHA3 has the potential to change how large B-cell lymphoma is managed, but we won't have these results until 2026. Other projects, like their CD70-directed therapy, look promising but have concerning safety signals, and they're also a long way from approval. Read the full article on Seeking AlphaIs Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies
Summary Allogene Therapeutics is a clinical-stage biotech developing allogeneic CAR T therapies for cancer and autoimmune diseases, with a focus on Cema-cel for LBCL. ALLO's advanced gene-editing platforms, like TALEN and CRISPR/Cas9, engineer donor-derived T cells to overcome autologous therapy limitations, enhancing treatment safety and effectiveness. Cema-cel, the company’s flagship therapy, is in a pivotal Phase 2 trial (ALPHA3) for large B-cell lymphoma, with potential regulatory submission by 2027. Despite a promising pipeline, ALLO faces cash runway concerns, making it a suitable DCA “buy” for investors aware of clinical trial risks. ALLO's valuation is attractive, with a low P/B multiple and sufficient liquidity to fund operations until the ALPHA3 trial's primary data readout in 2026. Read the full article on Seeking AlphaAllogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
Summary Allogene Therapeutics, Inc. initiation of phase 2 ALPHA3 study, using cema-cel for the treatment of patients with 1st-line large B-cell lymphoma, expected in mid-2024 with two data analysis in 2026. Results from phase 2 ALPHA2 trial, using cema-cel for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia, expected by end of 2024. Results from phase 1 TRAVERSE trial, using ALLO-316 for the treatment of CD70 positive clear cell renal cell carcinoma patients, expected by the end of 2024. Company gained rights from Servier to expand use of cema-cel for r/r CLL and 1st-line LBCL in European and U.K. territories; New potential to tap into >$9.5 billion market opportunity if approval is achieved for these indications. Read the full article on Seeking AlphaWe Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed
Key Insights Allogene Therapeutics to hold its Annual General Meeting on 5th of June Total pay for CEO David Chang...Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside
Summary Allogene Therapeutics has announced changes to its pipeline that extend its financial runway into 2026. The new ALPHA3 clinical trial for Allogene's Cema-Cel cancer treatment is set to begin in mid-2024, and if successful, investors could see significant returns on their investment. The company's Q42023 report evidenced its financial distress. However, the 2024 platform vision, in my opinion, will have a positive impact on its profitability in the midterm. Given the lack of short-term revenue catalysts, with clinical trials expected to yield results by the end of 2024, investors will be required to be patient, while experiencing high volatility and potential share dilutions this year. Read the full article on Seeking AlphaWe Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Rendimenti per gli azionisti
| ALLO | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | -12.3% | -1.8% | -0.3% |
| 1Y | 83.5% | 32.7% | 24.1% |
Ritorno vs Industria: ALLO ha superato il US Biotechs che ha restituito 32.7 % nell'ultimo anno.
Rendimento vs Mercato: ALLO ha superato il mercato US che ha restituito 24.1 % nell'ultimo anno.
Volatilità dei prezzi
| ALLO volatility | |
|---|---|
| ALLO Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di ALLO è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 15% ) di ALLO è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2017 | 151 | David Chang | allogene.com |
Allogene Therapeutics, Inc. è una società di immuno-oncologia in fase clinica che sviluppa e commercializza terapie a base di cellule T allogeniche geneticamente modificate per il trattamento del cancro e delle malattie autoimmuni. L'azienda sviluppa una pipeline di candidati multipli di cellule T CAR allogeniche utilizzando l'ingegneria proteica, l'editing genico, l'inserimento di geni e tecnologie proprietarie avanzate per la produzione di cellule T. L'azienda sta inoltre sviluppando la cemacacellula allogenica. L'azienda sta inoltre sviluppando cemacabtagene ansegedleucel (cema-cel), un candidato prodotto a base di cellule CAR T allogeniche ingegnerizzate che ha come bersaglio il CD19 per il trattamento del linfoma a grandi cellule B (LBCL).
Allogene Therapeutics, Inc. Riepilogo dei fondamenti
| ALLO statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$690.31m |
| Utili (TTM) | -US$173.76m |
| Ricavi(TTM) | n/a |
ALLO è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| ALLO Conto economico (TTM) | |
|---|---|
| Ricavi | US$0 |
| Costo del fatturato | US$131.96m |
| Profitto lordo | -US$131.95m |
| Altre spese | US$41.81m |
| Utili | -US$173.76m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -0.50 |
| Margine lordo | 0.00% |
| Margine di profitto netto | 0.00% |
| Rapporto debito/patrimonio netto | 0% |
Come si è comportato ALLO nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/18 08:58 |
| Prezzo dell'azione a fine giornata | 2026/05/15 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Allogene Therapeutics, Inc. è coperta da 31 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Jack Allen | Baird |
| Shanshan Xu | Berenberg |
| William Pickering | Bernstein |